Medical Condition News

RSS

DIS serves as marker for new methods to diagnose NERD

Gastroesophageal reflux disease is an important public health problem which is extremely common nowadays. Symptoms of GERD arise from the exposure of increased acid gastric contents into the lower part of the esophageal mucosa. Most patients with GERD have NERD with invisible mucosal damages under endoscopy.

31 Mar 2010

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept").

31 Mar 2010

Bright light therapy box for SAD, depression, bipolar disorder and sleep problems

Alaska Northern Lights manufactures a bright light therapy box that aids in treating chronic health problems such as seasonal affective disorder (SAD), depression, bipolar disorder and sleep problems. Sufferers of SAD, a form of clinical depression, include up to 25 percent of those living in northern latitudes who experience varying degrees of SAD during winter months when there is less natural light. Night shift workers are also susceptible to SAD which affects over one third of the population, or about 10.8 million Americans.

31 Mar 2010

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

A Kansas State University researcher is exploring the use of Chinese wolfberries to improve vision deficiencies that are common for type-2 diabetics.

31 Mar 2010

$Notch pathway could aid treatment of osteoporosis, fractures and arthritis$

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.

31 Mar 2010

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

The American Academy of Neurology (AAN) is awarding the 2010 Dreifuss-Penry Epilepsy Award to Martin J. Gallagher MD, PhD, with Vanderbilt University School of Medicine. Gallagher will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

The American Academy of Neurology (AAN) is awarding the 2010 Sheila Essey Award-An Award for ALS Research to Clive Svendsen, PhD, with the Cedars-Sinai Regenerative Medicine Institute in Los Angeles, CA. Svendsen will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

High radon levels in residential buildings can cause lung cancer

About 1900 deaths from lung cancer per year in Germany are due to radon within residential buildings. This was the conclusion reached in the current edition of Deutsches -rzteblatt International by Klaus Schmid of the University of Erlangen-Nuremberg and his coauthors (Dtsch Arztebl Int 2010; 107(11): 181-6).

31 Mar 2010

Vantage Communications becomes agency of record for ImThera Medical

Vantage Communications, an award-winning global PR firm, today announced that it is the agency of record for ImThera Medical, Inc. Within a few months, Vantage Communications successfully promoted ImThera and its medical device technology with original coverage garnered in top-tier publications such as Neurotech Insights, ENToday, The Gray Sheet, Sleep Review, Respiratory & Sleep Management, Respiratory Therapy, Medical Device Daily, and medGadget.

31 Mar 2010

New anti-inflammatory drug shows promise for treating inflammatory disorders

Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) remain the most common treatment to relieve symptoms of arthritis and other inflammatory disorders. But despite their widespread use (around 2.5 million Canadians have osteoarthritis) these medications are also known to cause severe, sometimes life-threatening adverse effects within the body, particularly in the gastrointestinal tract

31 Mar 2010

WOCN Society launches campaign to raise awareness about benefits of specialized care

Patients and families who are dealing with conditions such as non-healing wounds, bedsores, bladder and bowel incontinence and ostomy-related issues contend with physical symptoms, as well as social and emotional side effects. The impact on patients and families can exact an enormous toll. The Wound Ostomy & Continence Nurses Society is launching a campaign to raise awareness about the benefits of specialized care.

31 Mar 2010

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

31 Mar 2010

BVA unveils wide-view neurostimulator concept, prototype bionic eye

Bionic Vision Australia today unveils their wide-view neurostimulator concept - a bionic eye that will be implanted into Australia's first recipient of the technology.

31 Mar 2010

Drinking orange juice with fast-food meal may help prevent vascular inflammation

Eating foods containing flavonoids -- orange juice, in this case -- along with a high-fat, high-carbohydrate fast-food meal neutralizes the oxidative and inflammatory stress generated by the unhealthy food and helps prevent blood vessel damage, a new study by University at Buffalo endocrinologists shows.

31 Mar 2010

PMDD often misdiagnosed as major depression or other mood disorder

As science slowly, but continually, unravels the causes of disorders, it increasingly teases apart biological threads that, when spooled together, begin to take on the warp and weft of separate disorders.

31 Mar 2010

AgaMatrix, sanofi-aventis announce long-term partnership for BGM solutions

AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.

31 Mar 2010

Gore launches new consumer website to serve as patient resource on AAA

W. L. Gore & Associates announced the launch of a new consumer website, http://www.ultimatesaaave.com, which will serve as an enhanced patient resource on Abdominal Aortic Aneurysm.

31 Mar 2010

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide™/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

31 Mar 2010

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010